DelveInsight’s, NK Cell Therapy Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The NK Cell Therapy pipeline report also provides the inactive products analysis (dormant and terminated) along with the reasons for dormancy and discontinuation, wherever available. This report provides detailed profiles of the pipeline assets and comparative analysis of clinical and non-clinical stage products.
NK Cell Therapy Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis.
Download a PDF Sample Report- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight
NK Cell Therapy Pipeline Analysis
The report provides insights into:
- The report provides detailed insights about companies that are developing therapies in the NK Cell Therapy
- It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NK Cell Therapy
- NK Cell Therapy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- NK Cell Therapy Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NK Cell Therapy
The report is built using data and information traced from the researcher proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
NK Cell Therapy Emerging Drugs
- NKTR-214: Nektar therapeutics
- Monalizumab: Innate Pharma
- Bemarituzumab: Five Prime Therapeutics
- ALT 803: ImmunityBio
- CellProtect: XNK Therapeutics
- K-NK002: Kiadis Pharma
- NK-92: ImmunityBio
- WU-NK-101: Wugen
- Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
- ALECSAT: CytoVac
NK Cell Therapy Pipeline Therapeutic Analysis
There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.
NK Cell Therapy Pipeline Phases
DelveInsight’s report covers around 185+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
NK Cell Therapy Pipeline Companies
- ImmunityBio
- Cantargia
- CureTech
- Dynavax
- Cellid
- Abivax
- Affimed
- Celularity
- Glycostem Therapeutics (IPD Therapeutic)
- SYNIMMUNE
- Celyad
- Acepodia
- Allife Medical Science and Technology
- Bright Path Biotherapeutics
- Cytovia Therapeutics
- CytoImmune Therapeutics
- Exacis Biotherapeutics
- Novocellbio
- Kuur Therapeutics (Former name: Cell Medica)
- Fate Therapeutics
- Feldan Therapeutics
- iCell Gene Therapeutics
- Innate Pharma
- Nkarta Therapeutics
- Surface Oncology
- Kiadis Pharma
- Vycellix
- INmune Bio
- CiMass
- Glycostem
- Five Prime Therapeutics
- Multimmune GmbH
- Ambicion
- Bellicum Pharmaceuticals
- CARsgen therapeutics
- Kuur Therapeutics
- Celyad
- Dragonfly Therapeutics
- GamidaCell
- NantKwest
- Asclepius Technology Company
- AffimedTherapeutics
- Apceth Biopharma
- Zelluna Immunotherapy
- Catamaran Bio
- ONK Therapeutics
- Orgenesis
- Navrogen
- NKMAX
- Nektar Therapeutics
- Affimed Therapeutics
- HerbiCell
- Bristol-Myers Squibb
- CellProtect Nordic Pharmaceuticals
- CytoVac
- Green Cross Corporation
- NantKwest
- PersonGen BioTherapeutics (Suzhou)
- GT Biopharma (formerly Oxis International Inc.)
- Nektar Therapeutics
- Artiva Biotherapeutics
- Senti Biosciences
- oNKo-innate
- Affimed Therapeutics
- Agenus
- Chongqing Sidemu Biotechnology
- NKGen Biotech
- Caribou Biosciences
- Gamida-Cell
- Wugen
- Molmed
- Century Therapeutics
- KSQ Therapeutics
- GT Biopharma
- Shoreline Biosciences
- Indapta Therapeutics
- HebeCell
- Sorrento therapeutics
- Appia Bio
- Cellatoz Therapeutics
- Sanofi
- Glycotype
- CiMaas
- CoImmune
- Editas Medicine
- Healios
- Chimeric Therapeutics
- Rubius Therapeutics
- Oncternal Therapeutics
- MedXCell
- MiNK Therapeutics
- Phio Pharmaceuticals
- Biohaven Pharmaceuticals
- Lava therapeutics
- Allogene Therapeutics/Notch Therapeutics
- Onward therapeutics
- Miltenyi Biotec, and several others
NK Cell Therapy Pipeline Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
NK Cell Therapy Pipeline Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer (NK) cell therapy R&D. The therapies under development are focused on novel approaches to treat/improve Natural Killer (NK) cell therapy.
NK Cell Therapy Emerging Drugs Chapters
This segment of the Natural Killer (NK) cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Request a PDF Sample Report- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Natural Killer (NK) cell therapy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- NKTR-214: Nektar therapeutics
- Mid Stage Products (Phase II)
- CellProtect: XNK Therapeutics
- Early stage products (Phase I/II)
- Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
- Inactive Products
- Natural Killer (NK) cell therapy Key Companies
- Natural Killer (NK) cell therapy Key Products
- Natural Killer (NK) cell therapy- Unmet Needs
- Natural Killer (NK) cell therapy- Market Drivers and Barriers
- Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
- Natural Killer (NK) cell therapy Analyst Views
- Natural Killer (NK) cell therapy Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/